Trademark: 74236954
Status Date
Saturday, January 25, 2003
Registration Number
1970244
Registration Date
Tuesday, April 23, 1996
Filing Date
Monday, January 13, 1992
Published for Opposition
Tuesday, October 13, 1992
Cancellation Date
Saturday, January 25, 2003
5 hyperimmune intravenous immunoglobulins and vaccines used in the prevention and treatment of sepsis and infectious diseases associated with cystic fibrosis, cryptosporidiosis, cytomegalovirus, hepatitis B, varicella-zoster and HIV
The mark consists, in part, of a stylized representation of the antibody symbol.
The stippling on the drawing does not indicate color but is used to denote shading as a feature of the mark.
UVB
Jan 25, 2003
Cancelled Sec. 8 (6-Yr)
Apr 23, 1996
Registered-Principal Register
Feb 16, 1996
Allowed Principal Register - Sou Accepted
Feb 5, 1996
Assigned To Examiner
Jan 18, 1996
Statement Of Use Processing Complete
Nov 13, 1995
Use Amendment Filed
Aug 9, 1995
Extension 5 Granted
Jul 3, 1995
Extension 5 Filed
Feb 3, 1995
Extension 4 Granted
Dec 27, 1994
Extension 4 Filed
Jun 13, 1994
Extension 3 Granted
May 9, 1994
Extension 3 Filed
Mar 3, 1994
Extension 2 Granted
Dec 21, 1993
Extension 2 Filed
Jul 12, 1993
Extension 1 Granted
May 7, 1993
Extension 1 Filed
Jan 5, 1993
Noa Mailed - Sou Required From Applicant
Oct 13, 1992
Published For Opposition
Sep 11, 1992
Notice Of Publication
Jul 13, 1992
Approved For Pub - Principal Register
May 29, 1992
Correspondence Received In Law Office
Apr 8, 1992
Non-Final Action Mailed
Mar 6, 1992
Assigned To Examiner
Trademark Alertz updated from USPTO on 2030-01-24
